Members of the World Health Organisation (WHO), Champion Trial Investigators Meeting held between 7th and 8th March 2016 in Belgaum, India.
Prof. Qureshi (Principal Investigator) of the Champion Trial attended the WHO Champion Trial Investigators meeting in India. The Champion trial (A Phase III, Randomized, Double-Blind, Active Controlled, Multinational, Multicentre, Non-Inferiority Trial Using Carbetocin Room Temperature Stable (Rts) for the Prevention of Postpartum Haemorrhage during the Third Stage of Labour in Women Delivering Vaginally) has two primary objectives:
(1) To evaluate non-inferiority of carbetocin RTS 100 μg IM versus oxytocin 10 IU IM after vaginal delivery in the prevention of the composite endpoint “blood loss of 500 mL or more or the use of additional uterotonics” at one hour and up to two hours for women who continue to bleed after one hour.
(2) To evaluate non-inferiority of carbetocin RTS 100 µg IM versus oxytocin 10 IU IM in the prevention of sPPH (≥1000 mL blood loss) at one hour and up to two hours for women who continue to bleed after one hour.
The meeting brought together the investigators from 10 countries that are participating in the trial and the steering committee.
|WHO Champion Trial Investigators Meeting.pdf||170.74 KB|